Meeting
2020 ASCO Virtual Scientific Program
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
Authors
Kieuhoa T. Vo
University of California, San Francisco, CA
Kieuhoa T. Vo , Jennifer G. Michlitsch , Avanthi T. Shah , Joel M. Reid , Sarah A. Burhow , Eloise M. Graham , Fabienne Hollinger , Matthew A. Zapala , Janel Long-Boyle , Mi-Ok Kim , Katherine K. Matthay , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03139331
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10526)
DOI
10.1200/JCO.2020.38.15_suppl.10526
Abstract #
10526
Poster Bd #
413
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
First Author: Kieuhoa Tran Vo
Poster
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross
Poster
2017 ASCO Annual Meeting
Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
First Author: Sara Michele Federico
Poster
2013 ASCO Annual Meeting
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
First Author: Gregory Lawrence Beatty